{
    "nct_id": "NCT03193190",
    "official_title": "A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma\n* For patients in Cohort 1: no prior systemic treatment for PDAC\n* For patients in Cohort 2: disease progression during administration of either 5-FU- or gemcitabine-based first-line chemotherapy\n* Life expectancy greater than or equal to 3 months\n* Availability of a representative tumor specimen that is suitable for determination of programmed death-ligand 1 (PD-L1) and/or additional biomarker status via central testing\n* Measurable disease (at least one target lesion) according to RECIST v1.1\n* Adequate hematologic and end-organ function test results\n* Tumor accessible for biopsy\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs, as outlined for each specific treatment arm\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage procedure (i.e., more than one time per month)\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* History of leptomeningeal disease\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* Positive human immunodeficiency (HIV) test at screening or at any time prior to screening\n* Active hepatitis B or C virus infection or active tuberculosis\n* Severe infection within 4 weeks prior to initiation of study treatment\n* Prior allogeneic stem cell or solid organ transplantation\n* History of malignancy other than pancreatic carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death",
    "miscellaneous_criteria": ""
}